Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AURA-IPF inhaled nintedanib phase 2 study in idiopathic pulmonary fibrosis
2025-523431-19-00Phase 2Authorised
- Sponsor
- Avalyn Pharmaceuticals
- Start
- May 2026
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of AP02 in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Avalyn Pharmaceuticals. Primary endpoint: Change from baseline in morning pre-dose forced vital capacity at Week 12. Planned start May 2026; status: authorised.
02
Drugs
AP02
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2025-523431-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523431-19-00.